ADGM

8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)

Piper Sandler initiated coverage of Adagio Medical Holdings with a rating of Overweight and set a new price target of $3.00

8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)

Designed to Deliver Faster, More Efficient Ablation with Improved Usability on Established, Titratable, Endocardial-Approach ULTA Platform Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to expand the Company's FULCRUM-VT trial to evaluate the safety and effectiveness of the Company's next-generation vCLAS Ultra-Low Temperature Ablation (ULTA) Ventricular Ablation System for the treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT).

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating at the 25th Annual Needham Virtual Conference being held April 13-16, 2026. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cardiac (ULTA) ablation technology. ULTA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue, all

EFFECT - Adagio Medical Holdings, Inc. (0002006986) (Filer)

EFFECT - Adagio Medical Holdings, Inc. (0002006986) (Filer)

S-8 POS - Adagio Medical Holdings, Inc. (0002006986) (Filer)

POS AM - Adagio Medical Holdings, Inc. (0002006986) (Filer)

POS AM - Adagio Medical Holdings, Inc. (0002006986) (Filer)

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the pivotal results from the FULCRUM-VT study have been accepted for presentation in a late-breaking clinical science session at Heart Rhythm 2026 (HRS), the annual meeting of the Heart Rhythm Society. This is the first Investigational Device Exemption (IDE) study powered to evaluate the safety and effectiveness of Ultra-Low Temperature Ablation ("ULTA", formerly "ULTC") for the treatment of scar-related ventricular tachycardia (VT) in both ischemic and non-ischemic population. "Having FULCRUM-VT data

POS AM - Adagio Medical Holdings, Inc. (0002006986) (Filer)

POS AM - Adagio Medical Holdings, Inc. (0002006986) (Filer)

424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

10-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)

8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the fourth quarter ended December 31, 2025. Fourth Quarter and Recent Business Highlights: Announced the peer-reviewed publication in Circulation: Arrythmia and Electrophysiology, highlighting results from the U.S. Early Feasibility Study evaluating ultralow temperature cardiac ablation ("ULTA") for the treatment of scar-related ventricular tachycardia ("VT"), which demonstrated a favorable safety profile and no device- or procedure-related major adverse events in a real-world patie

Highlights Improvements in Next Generation ULTA Catheter, Including Potential 50-75% Reduction in Ablation Time Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of pre-clinical results of the Company's next generation ultra-low temperature ablation ("ULTA") technology designed to treat ventricular arrhythmias. The publication, which is titled "Initial Pre‐Clinical Evaluation of the Augmented Ultra‐Low Temperature Cryoablation Catheter for Ventricular Ablation" was published in the Journal of Cardiovascular Electrophysiology and describes s

vCLASTM Used to Treat Patients with No Satisfactory Approved Treatment and/or Failed RF or PFA Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful completion of 13 ventricular ablation procedures at leading institutions using the Company's proprietary Ultra-Low Temperature Ablation (ULTA) technology under Expanded Access authorization from the U.S. Food and Drug Administration (FDA). The procedures addressed recurrent, symptomatic ventricular tachycardia (VT) or premature ventricular contractions (PVC) in patients who had previously failed abl

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating in the 38th Annual Roth Conference on March 23-24, 2026 in Laguna Niguel, CA and will be hosting one-on-one meetings with investors at the conference. For more information on the 38th Annual ROTH Conference, or to schedule a meeting with Adagio Medical management, please contact your ROTH representative or you may also email your request to ir@adagiomedical.com. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commerci

4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA. Presentation Information A live webcast and replay of the session will be accessible at https://event.summitcast.com or on the Company's website at https://investors.adagiomedical.com. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel,

SCHEDULE 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)